Merck's jobs axe is put to work

There's a lot of rumbling in the blogosphere about the Merck job-chopping block. Last fall Merck announced it would shed 6,800 jobs--and now, the drugmaker is lowering the boom. Or so we're told.

Derek Lowe at In the Pipeline is hearing firsthand from Merck folks that an across-the-board cutback in R&D is going on as we speak. Research types at all R&D sites are getting pink slips.

And with Merck and Schering-Plough destined to merge later this year, the job cuts are due to step up a notch. If the current round is part of the previously announced restructuring plan, they're just a warm-up for an expected 16,000 or so additional cuts. All told, Merck and Schering-Plough's workforce is expected to shrink by 15 percent.

- read the post at In The Pipeline

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.